Oxidase activity of ceruloplasmin and some acute phase reactant and trace element concentrations in serum of patients with chronic lymphocytic leukemia

被引:12
|
作者
Gundogdu, M. [1 ]
Kaya, H.
Gulcin, I.
Erdem, F.
Cayir, K.
Keles, M.
Yilmaz, A.
机构
[1] Ataturk Univ, Sch Med, Dept Internal Med, TR-25240 Erzurum, Turkey
[2] Mustafa Kemal Univ, Dept Internal Med, Sch Med, Antakya, Turkey
[3] Dept Chem Sci & Art Fac, Erzurum, Turkey
[4] Nenehatun Obstetr & Gynecol Hosp, Dept Biochem, Erzurum, Turkey
关键词
D O I
10.1258/rsmsmj.52.1.24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present study, we aimed to investigate the parameters in serum of patients with chronic lymphocytic leukaemia (CLL) and correlate with the cancer stage. The serum concentrations of ceruloplasmin, a-1-acid glycoprotein, albuminumin, transferrin, copper, zinc, manganese, and ceruloplasmin oxidase activity were measured, and compared with those from a healthy control group. The serum from 34 patients with CLL were extracted before chemotherapy. Serum transferrin, allbuminumin and Zinc concentrations were lower in patients with CLL while serum a-1-acid glycoprotein, ceruloplasmin, copper concentrations, and ceruloplasmin oxidase activity were higher in CLL patients when compared with the control group. Although serum manganese concentration was lower in CLL groups than in the control group, the difference was not statistically significant. Serum transferrin concentration was lower in the early stage group compared with the advanced stage. Serum ceruloplasmin level positively correlated with serum ceruloplasmin oxidase activity in patients from the early stage group. Serum ceruloplasmin level positively correlated with serum ceruloplasmin oxidase activity in patients with advanced stage. In conclusion, increased serum ceruloplasmin oxidase activity, ceruloplasmin, a-1-acid glycoprotein, copper levels and decreased transferrin and albuminumin, unchanged manganese levels are associated with CLL and appear to be a consequence of the disease itself.
引用
收藏
页码:24 / 27
页数:4
相关论文
共 46 条
  • [31] Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) - Interim Analysis.
    Sher, Taimur
    Azar, Jose
    Spurgeon, Stephen
    Catalano, John
    Furman, Richard R.
    Prince, Miles
    Bartlett, Nancy L.
    Durrant, Simon
    Boccia, Ralph
    Masood, Aisha
    Lyman, Scott
    Cantey-Kiser, Jean
    Sheridan, William P.
    Chanan-Khan, Asher
    BLOOD, 2010, 116 (21) : 601 - 601
  • [32] Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing phase II study.
    Wiestner, Adrian
    Herman, Sarah
    Mustafa, Rashida
    Valdez, Janet
    Jones, Jade
    Saba, Nakhle
    Lipsky, Andrew
    Arthur, Diane C.
    Marti, Gerald
    Thomas, Francine
    Maric, Irina
    Pittaluga, Stefania
    Tian, Xin
    Soto, Susan
    Aue, Georg
    Farooqui, Mohammed Z.
    CANCER RESEARCH, 2013, 73 (08)
  • [33] THE PRESENCE OF CIRCULATING DEOXYRIBONUCLEIC-ACID (DNA) IN PATIENTS WITH ACUTE OR CHRONIC LEUKEMIA - RELATION TO SERUM ANTI-DNA ANTIBODIES AND CLQ BINDING-ACTIVITY
    CARPENTIER, NA
    IZUI, S
    ROSE, LM
    LAMBERT, PH
    MIESCHER, PA
    HUMAN LYMPHOCYTE DIFFERENTIATION, 1981, 1 (02): : 93 - 104
  • [34] Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).
    Lin, Thomas S.
    Fischer, Beth
    Blum, Kristie A.
    Andritsos, Leslie A.
    Jones, Jeffrey A.
    Moran, Mollie E.
    Broering, Sarah
    Heerema, Nyla A.
    Lozanski, Gerard
    Schaaf, Larry J.
    Mahoney, Linda S.
    Johnson, Amy J.
    Smith, Lisa L.
    Wagner, Amy J.
    Raymond, Chelsey A.
    Phelps, Mitch
    Dalton, James T.
    Grever, Michael R.
    Byrd, John C.
    BLOOD, 2007, 110 (11) : 913A - 913A
  • [35] Asparaginase (ASNase) activity, amino acid serum concentrations and clinical outcome in pediatric patients with higher risk acute lymphoblastic leukemia (HR ALL): A report from CCG-1961.
    Panosyan, EH
    Grigoryan, RS
    Avramis, LA
    Jaques, JD
    Seibel, NL
    Ettinger, LJ
    Gaynon, PS
    Siegel, SE
    Fingert, HJ
    Avramis, VI
    BLOOD, 2003, 102 (11) : 378A - 378A
  • [36] An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Roberts, Andrew W.
    Seymour, John F.
    Brown, Jennifer R.
    Wierda, William G.
    Kipps, Thomas J.
    Carney, Dennis
    Xiong, Hao
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2009, 114 (22) : 364 - 364
  • [37] MK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the t315I BCR-ABL mutation.
    Bergstrom, Donald A.
    Clark, Jason B.
    Xiao, Alan
    Griffiths, Matthew
    Falcon, Susannah
    Pollard, John
    Freedman, Steven J.
    Giles, Francis
    BLOOD, 2006, 108 (11) : 192A - 192A
  • [38] A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph plus ) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
    Craig, A. R.
    Kantarjian, H. M.
    Cortes, J. E.
    Jones, D.
    Hochhaus, A.
    O'Brien, S.
    Rios, M.
    Zander, C.
    Gleich, L.
    Carroll, E. P.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] A phase 1/2 study of SKI-606, a dual inhibitor of src and abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib.
    Cortes, Jorge
    Kantarjian, Hagop M.
    Baccarani, Michele
    Brummendorf, Tim H.
    Liu, Delong
    Ossenkoppele, Gert
    Volkert, Angela D. G.
    Hewes, Becker
    Moore, Laurence
    Zacharchuk, Charles
    Gambacorti, Carlo
    BLOOD, 2006, 108 (11) : 54A - 54A
  • [40] Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.
    Flynn, Joseph M.
    Jones, Jeffrey A.
    Andritsos, Leslie
    Blum, Kristie A.
    Johnson, Amy J.
    Hessler, Josh
    Wiley, Elizabeth
    Poon, Jennifer
    Small, Karen
    Statkevich, Paul
    Grever, Michael R.
    Bannerji, Rajat
    Byrd, John C.
    BLOOD, 2010, 116 (21) : 600 - 601